Joanne Imperial left the role of Director at CapsoVision, Inc. As of November 6, 2026, CapsoVision, Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 2, 2026, naming 1 departure (Form 8-K, July 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like CapsoVision, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
CapsoVision, Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-02. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as CapsoVision, Inc files it.
Also on the record for CapsoVision, Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 4, 2026 | Stake report, Schedule 13G/A, by Eliyahou Harari | 13.2% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by Eliyahou Harari | 10.2% of the class | 5%+ stakes | Source |
| April 17, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| April 15, 2026 | Stake report, Schedule 13G/A, by Shen Ching Hang | 12.8% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13G/A, by CID Greater China Venture Capital Fund III, L.P. | — | 5%+ stakes | Source |
| December 22, 2025 | Stake report, Schedule 13G, by Shen Ching Hang | 8.5% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G, by Kioxia Corporation | 7.4% of the class | 5%+ stakes | Source |
| October 29, 2025 | Stake report, Schedule 13G, by CID Greater China Venture Capital Fund III, L.P. | 6.7% of the class | 5%+ stakes | Source |
| October 14, 2025 | Stake report, Schedule 13G, by Eliyahou Harari | 9.2% of the class | 5%+ stakes | Source |
| July 3, 2025 | IPO filing, Form 424B4 | $5 a share | IPO filings | Source |
| June 27, 2025 | IPO filing, Form S-1/A | $5 to $5.5 a share | IPO filings | Source |
| June 13, 2025 | IPO filing, Form S-1/A | $5 to $5.5 a share | IPO filings | Source |
Selling to them or working with them? See who runs CapsoVision, Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on CapsoVision, Inc and the records around it.
CapsoVision, Inc elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Watch CapsoVision, Inc
Get an email when CapsoVision, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CapsoVision, Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on CapsoVision, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CapsoVision, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-02 | Out | Director | 8-K, 2026-07-02 |
Who leads CapsoVision, Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Joanne Imperial, departure reported (filed 2026-07-02). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on CapsoVision, Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at CapsoVision, Inc, with the record behind each one.
Find candidates like Director at CapsoVision, IncEvery change, in the filing's words
Departing: Joanne Imperial, Director
Resignation of Dr. Joanne Imperial as a Director On July 1, 2026, Dr. Joanne Imperial stepped down from the Board as a Class I director and as a member of the Compensation Committee of the Board, effective immediately.
- Appointment of Dr. David S. Shields as a Director On July 1, 2026, the Board of Directors (the "Board") of CapsoVision Inc. (the "Company") appointed Dr. David Stanley Shields to serve as a Class I director of the Board and as a member of the Compensation Committee of the Board, in each case effective immediately to fill the vacancy upon the resignation of Dr. Imperial.
- Dr. David S. Shields, age 75, is a board-certified gastroenterologist with more than four decades of experience in academic medicine, clinical gastroenterology, advanced endoscopy, and digestive disease management.
- Since 1986, he has maintained a private gastroenterology consulting practice in Palo Alto, California, providing comprehensive care to patients with gastrointestinal and liver disorders.
- Dr. Shields previously served as Assistant Professor of Medicine in the Division of Gastroenterology at Stanford University School of Medicine and served as Director of Endoscopy at Stanford Hospital.
- Throughout his career, he has remained actively involved in clinical education and physician training.
- He currently serves as a gastroenterology consultant and clinician at both San Mateo County Medical Center and the Palo Alto Veterans Affairs Health Care System, where he continues to teach medical residents and gastroenterology fellows.
Tools for this story
Each opens in a new tab, filled in for CapsoVision, Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.